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Alström syndrome (AS) is a complex disorder whose mani-
festations include retinal degeneration, sensorineural hear-
ing loss, cardiomyopathy, liver fibrosis, and severe insulin
resistance. It is caused by biallelic loss-of-function muta-
tions in the ALMS1 gene, encoding a large centrosomal
protein of poorly understood function. Although the syn-
drome encompasses several cardinal features of ciliopathies,
primary cilia have been reported to be morphologically
normal in primary cells from patients with AS. In order
to dissect out the cellular pathology of AS in humans we
have now, in a project led by Alström UK, assembled a
bank of dermal fibroblasts from patients with AS. All 11
cell lines studied to date show normal primary cilia on
serum starvation. 3/11 lines express near normal levels of
ALMS1 protein at the centrosome despite biallelic ALMS1
mutations, which will permit refinement of existing geno-
type-phenotype correlations in AS. We have also generated
induced pluripotent stem cells that will be differentiated
into cell types relevant to the organ-specific pathologies of
AS including cardiomyocytes, hepatocytes and adipocytes.
Finally we have used lentivirally-mediated expression of the
adipose differentiation regulator PPARgamma2 to repro-
gramme human dermal fibroblasts to adipocytes. We have
developed a highly efficient protocol to produce cells that
accumulate triglyceride, show a pattern of gene expression
consistent with adipocytes, secrete adiponectin and leptin,
and respond physiologically to insulin. Collectively these
developments constitute a valuable cellular resource for
studying the cellular pathology of AS, and may form the
basis of preclinical treatment screens in future.
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